Vir Biotechnology names Aziz Sawaf as new CFO effective October 5, 2026
Theravance Biopharma's former CFO takes over Vir's finance, IT and investor relations functions as Brent Sabatini steps down from interim duties.
SEC filing
Latest
20 stories
Today
Friday, September 25
Gilead registers two Phase 2 trials: PBC combo study and weekly oral HIV regimen
Wednesday, September 23
Corcept names Justin Gunn to succeed retiring endocrinology president Sean Maduck
Sean Maduck steps down as President of Corcept's Endocrinology division effective October 1, 2026, with Justin Gunn taking over the role.
SEC filing
Thursday, September 10
King's College Hospital registers PK study of Gilead-partnered TAF regimen in kidney disease
Wednesday, August 26
NIAID-led IMPAACT 2026 pharmacokinetic study terminated early, results posted
Tuesday, August 25
FDA grants orphan drug status to Lakefront's gamgertamig for pemphigus
The designation adds to earlier Fast Track and Orphan Drug status the drug already holds for two other autoimmune blood disorders.
SEC filing
Tuesday, August 18
Cocrystal Pharma adds Carol Brosgart, MD to board of directors
The antiviral biotech named the physician-scientist and veteran biopharma board member to its board effective August 12, 2026.
SEC filing (2)
Kite's ZUMA-2 Cohort 3 trial in BTKi-naive mantle cell lymphoma completes, results posted
Thursday, August 13
Assembly Bio reports Q2 2026 results, expands ABI-6250 into cholestatic liver disease
Company closed a $115 million financing and disclosed Gilead's plan to advance GS-1179 into Phase 2 for genital herpes by year-end 2026.
SEC filing
Vanderbilt registers Phase 2 Lazarus trial testing IT therapy to prevent ICANS after CAR T
Wednesday, August 12
Xilio gets FDA clearance for XTX501 IND, reports Q2 2026 results
The bispecific PD-1/masked IL-2 candidate is set to begin Phase 1 dosing in the second half of 2026 as Xilio's cash runway extends into early 2028.
SEC filing
Lakefront reports H1 2026 results after closing Ouro Medicines deal with Gilead
The company said it expects at least €1.6 billion in cash to remain after funding its lead program, gamgertamig, to first approval.
SEC filing
Wednesday, August 5
NJCRI registers transgender liver health study with Gilead as collaborator
Kymera moves up KT-621 atopic dermatitis data after fast enrollment
Faster-than-planned enrollment in the STAT6 degrader's Phase 2b trial pulls the readout forward to year-end 2026 and sets up an earlier Phase 3 start.
SEC filing
Tuesday, August 4
Rani Therapeutics adds Michelle Gilson to board, names her audit chair
The appointment took effect August 1, 2026, and Gilson brings prior CFO and equity research experience in biotech to the role.
SEC filing
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readouts
The company posted a GAAP diluted loss of $8.45 per share tied to acquisition charges while raising full-year product sales guidance.
SEC filing
Monday, August 3
Ascentage Pharma names new Chief Business Officer and Chief Commercial Officer
The company appointed Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO on August 2, 2026, dividing global deal-making from U.S. and ex-China commercial duties.
SEC filing